| Lung CancerA17:G22) | ||||||
| No. | Study Title | Principle Investigator | Sponsor | Type | Recruiting | Study status |
| 1 | APPLE study: Feasibility and activity of AZD9291 (osimertinib) treatment on Positive Plasma T790M in EGFR mutant NSCLC patients. | Dr. Kamal Al-Rabi | EORTC | Clinical Trial | No | Ongoing |
| 2 | CANOPY 2 study: A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of canakinumab in combination with docetaxel versus placebo in combination with docetaxel in subjects with non-small cell lung cancer (NSCLC) previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (CANOPY-2). | Dr. Sameer Yaser | Novartis | Clinical Trial | No | Ongoing |
| 3 | CANOPY A study: A phase III, multicenter, randomized, double blind, placebo controlled study evaluating the efficacy and safety of canakinumab versus placebo as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cmN2) completely resected (R0) non-small cell. | Dr. Sameer Yaser | Novartis | Clinical Trial | Yes | Ongoing |
| 4 | EORTC 1825 ALKALINE study: Activity of Lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with 2nd generation ALK inhibitor. | Dr. Kamal Al-Rabi | EORTC | Clinical Trial | Pending | Pending |